This Vaginal and Vulval Inflammatory Disease Treatment market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
The vaginal and vulval inflammatory disease treatment market size has grown strongly in recent years. It will grow from $2.87 billion in 2024 to $3.06 billion in 2025 at a compound annual growth rate (CAGR) of 6.65%. The growth during the historic period can be attributed to the rising incidence of vaginal infections, growing awareness of women's health, improvements in healthcare infrastructure, an aging population, and increasing urbanization.
The vaginal and vulval inflammatory disease treatment market size is expected to see strong growth in the next few years. It will grow to $3.92 billion in 2029 at a compound annual growth rate (CAGR) of 6.39%. The growth in the forecast period is expected to be driven by greater awareness of vulvovaginal health, rising demand for non-invasive treatments, an increase in chronic inflammatory diseases, expanded access to healthcare, and a growing number of healthcare professionals. Key trends in the forecast period include advancements in diagnostic tools, the integration of artificial intelligence (AI) in diagnostics, the rise of home-based care solutions, the development of vaginal vaccines, and the adoption of minimally invasive surgical techniques.
The rise in diabetes cases is anticipated to fuel the expansion of the vaginal and vulval inflammatory disease treatment market. Diabetes is a chronic condition marked by high blood sugar levels due to the body’s inability to produce or use insulin properly. The growing prevalence of diabetes can be linked to factors such as sedentary lifestyles, poor eating habits, increasing obesity, genetic factors, and an aging population. Treatments for vaginal and vulval inflammatory diseases help diabetes patients by reducing recurrent infections, which are frequent due to high blood sugar and compromised immune function, while also improving insulin sensitivity and overall blood sugar management. For example, in March 2024, the Office for Health Improvement & Disparities in the UK reported a 22% increase in individuals with type 1 diabetes receiving all recommended care processes from March 2022 to March 2023, and a 21% increase for type 2 diabetes. Additionally, 37.9% achieved target HbA1c levels, the highest ever recorded by the National Diabetes Audit (NDA). As a result, the growing incidence of diabetes is driving the growth of the vaginal and vulval inflammatory disease treatment market.
Key players in the vaginal and vulval inflammatory disease treatment market are focusing on the development of innovative products, such as vaginal synbiotics, to improve treatment effectiveness and patient outcomes. A vaginal synbiotic is a combination of probiotics and prebiotics designed to support the vaginal microbiome, maintain balance, and prevent infections. For example, in May 2024, Seed Health Inc., a biotechnology company based in the US, launched VS-01, a pioneering product intended to transform vaginal care. This first-of-its-kind product is scientifically formulated to promote vaginal health by supporting microbiome balance. VS-01 uses a proprietary blend of probiotics that target the vaginal microbiome, helping to preserve its natural defenses. By utilizing advanced microbiome science, this product addresses imbalances and discomfort, offering a comprehensive solution for women aiming to improve vaginal health.
In March 2023, GSK plc, a pharmaceutical company from the UK, entered into an exclusive partnership with SCYNEXIS Inc. to license and commercialize Brexafemme (ibrexafungerp). Through this collaboration, GSK plc seeks to expand its infectious disease portfolio by marketing Brexafemme for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC, as well as advancing its development for invasive candidiasis. This partnership addresses the growing demand for effective antifungal treatments. SCYNEXIS Inc., a US-based company, specializes in treatments for vulvovaginal candidiasis (VVC).
Major players in the vaginal and vulval inflammatory disease treatment market are Pfizer Incorporated, Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Limited, Sandoz International GmbH, Hologic Inc., Ferring Pharmaceuticals, Venus Concept Inc., Kyung Hee University Medical Center, Duchesnay Inc., Evofem Biosciences Inc., SEID Lab, Curive Healthcare Inc., Replens, MC2 Therapeutics ApS, FemiClear.
North America was the largest region in the vaginal and vulval inflammatory disease treatment market in 2024. The regions covered in vulval inflammatory disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the vaginal and vulval inflammatory disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Vaginal and vulval inflammatory diseases encompass a group of conditions marked by inflammation of the vaginal and vulvar tissues, which may result in symptoms such as irritation, swelling, pain, redness, and sometimes infection. These conditions are commonly caused by bacterial, viral, or fungal infections, allergic reactions, skin disorders, or autoimmune diseases. Treatment generally involves addressing the root cause of the condition and managing symptoms through appropriate medical treatments and lifestyle changes.
The primary indications for treating vaginal and vulval inflammatory diseases include vaginal dryness, vaginal burning, vaginal discharge, genital itching, recurrent urinary tract infections, urinary incontinence, and other related issues. Vaginal dryness, often linked to reduced moisture in the vaginal area, is typically caused by hormonal changes, such as those seen during menopause. Treatment options include anti-itch medications, corticosteroid ointments, and emollients, and these are utilized by various end-users, including hospital pharmacies, specialty clinics, and other healthcare providers.
The vaginal and vulval inflammatory diseases treatment market research report is one of a series of new reports that provides vaginal and vulval inflammatory diseases treatment market statistics, including the vaginal and vulval inflammatory diseases treatment industry global market size, regional shares, competitors with the vaginal and vulval inflammatory diseases treatment market share, detailed vaginal and vulval inflammatory diseases treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the vaginal and vulval inflammatory diseases treatment industry. This dark store market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The vaginal and vulval inflammatory disease treatment market includes revenues earned by entities by providing services diagnostic services, pharmaceutical treatment services, and therapeutic procedures and related products such as antifungal creams, antibiotics, anti-inflammatory medications, hormonal therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The vaginal and vulval inflammatory disease treatment market size has grown strongly in recent years. It will grow from $2.87 billion in 2024 to $3.06 billion in 2025 at a compound annual growth rate (CAGR) of 6.65%. The growth during the historic period can be attributed to the rising incidence of vaginal infections, growing awareness of women's health, improvements in healthcare infrastructure, an aging population, and increasing urbanization.
The vaginal and vulval inflammatory disease treatment market size is expected to see strong growth in the next few years. It will grow to $3.92 billion in 2029 at a compound annual growth rate (CAGR) of 6.39%. The growth in the forecast period is expected to be driven by greater awareness of vulvovaginal health, rising demand for non-invasive treatments, an increase in chronic inflammatory diseases, expanded access to healthcare, and a growing number of healthcare professionals. Key trends in the forecast period include advancements in diagnostic tools, the integration of artificial intelligence (AI) in diagnostics, the rise of home-based care solutions, the development of vaginal vaccines, and the adoption of minimally invasive surgical techniques.
The rise in diabetes cases is anticipated to fuel the expansion of the vaginal and vulval inflammatory disease treatment market. Diabetes is a chronic condition marked by high blood sugar levels due to the body’s inability to produce or use insulin properly. The growing prevalence of diabetes can be linked to factors such as sedentary lifestyles, poor eating habits, increasing obesity, genetic factors, and an aging population. Treatments for vaginal and vulval inflammatory diseases help diabetes patients by reducing recurrent infections, which are frequent due to high blood sugar and compromised immune function, while also improving insulin sensitivity and overall blood sugar management. For example, in March 2024, the Office for Health Improvement & Disparities in the UK reported a 22% increase in individuals with type 1 diabetes receiving all recommended care processes from March 2022 to March 2023, and a 21% increase for type 2 diabetes. Additionally, 37.9% achieved target HbA1c levels, the highest ever recorded by the National Diabetes Audit (NDA). As a result, the growing incidence of diabetes is driving the growth of the vaginal and vulval inflammatory disease treatment market.
Key players in the vaginal and vulval inflammatory disease treatment market are focusing on the development of innovative products, such as vaginal synbiotics, to improve treatment effectiveness and patient outcomes. A vaginal synbiotic is a combination of probiotics and prebiotics designed to support the vaginal microbiome, maintain balance, and prevent infections. For example, in May 2024, Seed Health Inc., a biotechnology company based in the US, launched VS-01, a pioneering product intended to transform vaginal care. This first-of-its-kind product is scientifically formulated to promote vaginal health by supporting microbiome balance. VS-01 uses a proprietary blend of probiotics that target the vaginal microbiome, helping to preserve its natural defenses. By utilizing advanced microbiome science, this product addresses imbalances and discomfort, offering a comprehensive solution for women aiming to improve vaginal health.
In March 2023, GSK plc, a pharmaceutical company from the UK, entered into an exclusive partnership with SCYNEXIS Inc. to license and commercialize Brexafemme (ibrexafungerp). Through this collaboration, GSK plc seeks to expand its infectious disease portfolio by marketing Brexafemme for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC, as well as advancing its development for invasive candidiasis. This partnership addresses the growing demand for effective antifungal treatments. SCYNEXIS Inc., a US-based company, specializes in treatments for vulvovaginal candidiasis (VVC).
Major players in the vaginal and vulval inflammatory disease treatment market are Pfizer Incorporated, Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Limited, Sandoz International GmbH, Hologic Inc., Ferring Pharmaceuticals, Venus Concept Inc., Kyung Hee University Medical Center, Duchesnay Inc., Evofem Biosciences Inc., SEID Lab, Curive Healthcare Inc., Replens, MC2 Therapeutics ApS, FemiClear.
North America was the largest region in the vaginal and vulval inflammatory disease treatment market in 2024. The regions covered in vulval inflammatory disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the vaginal and vulval inflammatory disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Vaginal and vulval inflammatory diseases encompass a group of conditions marked by inflammation of the vaginal and vulvar tissues, which may result in symptoms such as irritation, swelling, pain, redness, and sometimes infection. These conditions are commonly caused by bacterial, viral, or fungal infections, allergic reactions, skin disorders, or autoimmune diseases. Treatment generally involves addressing the root cause of the condition and managing symptoms through appropriate medical treatments and lifestyle changes.
The primary indications for treating vaginal and vulval inflammatory diseases include vaginal dryness, vaginal burning, vaginal discharge, genital itching, recurrent urinary tract infections, urinary incontinence, and other related issues. Vaginal dryness, often linked to reduced moisture in the vaginal area, is typically caused by hormonal changes, such as those seen during menopause. Treatment options include anti-itch medications, corticosteroid ointments, and emollients, and these are utilized by various end-users, including hospital pharmacies, specialty clinics, and other healthcare providers.
The vaginal and vulval inflammatory diseases treatment market research report is one of a series of new reports that provides vaginal and vulval inflammatory diseases treatment market statistics, including the vaginal and vulval inflammatory diseases treatment industry global market size, regional shares, competitors with the vaginal and vulval inflammatory diseases treatment market share, detailed vaginal and vulval inflammatory diseases treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the vaginal and vulval inflammatory diseases treatment industry. This dark store market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The vaginal and vulval inflammatory disease treatment market includes revenues earned by entities by providing services diagnostic services, pharmaceutical treatment services, and therapeutic procedures and related products such as antifungal creams, antibiotics, anti-inflammatory medications, hormonal therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Vaginal and Vulval Inflammatory Disease Treatment Market Characteristics3. Vaginal and Vulval Inflammatory Disease Treatment Market Trends and Strategies4. Vaginal and Vulval Inflammatory Disease Treatment Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Vaginal and Vulval Inflammatory Disease Treatment Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Vaginal and Vulval Inflammatory Disease Treatment Market34. Recent Developments in the Vaginal and Vulval Inflammatory Disease Treatment Market
5. Global Vaginal and Vulval Inflammatory Disease Treatment Growth Analysis and Strategic Analysis Framework
6. Vaginal and Vulval Inflammatory Disease Treatment Market Segmentation
7. Vaginal and Vulval Inflammatory Disease Treatment Market Regional and Country Analysis
8. Asia-Pacific Vaginal and Vulval Inflammatory Disease Treatment Market
9. China Vaginal and Vulval Inflammatory Disease Treatment Market
10. India Vaginal and Vulval Inflammatory Disease Treatment Market
11. Japan Vaginal and Vulval Inflammatory Disease Treatment Market
12. Australia Vaginal and Vulval Inflammatory Disease Treatment Market
13. Indonesia Vaginal and Vulval Inflammatory Disease Treatment Market
14. South Korea Vaginal and Vulval Inflammatory Disease Treatment Market
15. Western Europe Vaginal and Vulval Inflammatory Disease Treatment Market
16. UK Vaginal and Vulval Inflammatory Disease Treatment Market
17. Germany Vaginal and Vulval Inflammatory Disease Treatment Market
18. France Vaginal and Vulval Inflammatory Disease Treatment Market
19. Italy Vaginal and Vulval Inflammatory Disease Treatment Market
20. Spain Vaginal and Vulval Inflammatory Disease Treatment Market
21. Eastern Europe Vaginal and Vulval Inflammatory Disease Treatment Market
22. Russia Vaginal and Vulval Inflammatory Disease Treatment Market
23. North America Vaginal and Vulval Inflammatory Disease Treatment Market
24. USA Vaginal and Vulval Inflammatory Disease Treatment Market
25. Canada Vaginal and Vulval Inflammatory Disease Treatment Market
26. South America Vaginal and Vulval Inflammatory Disease Treatment Market
27. Brazil Vaginal and Vulval Inflammatory Disease Treatment Market
28. Middle East Vaginal and Vulval Inflammatory Disease Treatment Market
29. Africa Vaginal and Vulval Inflammatory Disease Treatment Market
30. Vaginal and Vulval Inflammatory Disease Treatment Market Competitive Landscape and Company Profiles
31. Vaginal and Vulval Inflammatory Disease Treatment Market Other Major and Innovative Companies
35. Vaginal and Vulval Inflammatory Disease Treatment Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Vaginal and Vulval Inflammatory Disease Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on vaginal and vulval inflammatory disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for vaginal and vulval inflammatory disease treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vaginal and vulval inflammatory disease treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Vaginal Dryness; Vaginal Burning; Vaginal Discharge; Genital Itching; Recurrent Urinary Tract Infections; Urinary Incontinence; Other Indications2) by Treatment: Anti-Itch Medications; Corticosteroid Ointments; Anti-Itch Emollients
3) by End User: Hospital Pharmacies; Specialty Clinics; Other End-Users
Subsegments:
1) by Vaginal Dryness: Hormonal Therapy; Non-Hormonal Moisturizers; Lubricants and Topical Agents2) by Vaginal Burning: Anti-inflammatory Creams and Gels; Topical Steroids; Pain Relief Medications
3) by Vaginal Discharge: Antifungal Treatments; Antibacterial Treatments; Probiotics and Prebiotics
4) by Genital Itching: Antihistamines; Topical Corticosteroids; Antifungal Treatments
5) by Recurrent Urinary Tract Infections (UTIs): Antibiotics; Probiotics; Cranberry-based Supplements
6) by Urinary Incontinence: Behavioral Therapy; Medications (Anticholinergics, Beta-3 Agonists); Surgical Interventions
7) by Other Indications: Lichen Sclerosus; Vaginal Atrophy; Pelvic Floor Dysfunction; Vulvar Vestibulitis
Key Companies Profiled: Pfizer Incorporated; Bayer AG; Sanofi S.A.; Bristol-Myers Squibb Company; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The companies featured in this Vaginal and Vulval Inflammatory Disease Treatment market report include:- Pfizer Incorporated
- Bayer AG
- Sanofi S.A.
- Bristol-Myers Squibb Company
- Novartis AG
- GlaxoSmithKline plc
- Eli Lilly and Company
- Teva Pharmaceutical Industries Limited
- Sandoz International GmbH
- Hologic Inc.
- Ferring Pharmaceuticals
- Venus Concept Inc.
- Kyung Hee University Medical Center
- Duchesnay Inc.
- Evofem Biosciences Inc.
- SEID Lab
- Curive Healthcare Inc.
- Replens
- MC2 Therapeutics ApS
- FemiClear
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | April 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 3.06 Billion |
| Forecasted Market Value ( USD | $ 3.92 Billion |
| Compound Annual Growth Rate | 6.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 20 |
